Download Table of contents

New Cytokines CE ELISA kits
Launching File
Part5: Hematopoiesis-Differentiation
Products:
Format:
Size:
cat#
Product Description
KAPMS120
human IL-5
KAPMS113
human IL-13
KAPMS105
human TGF-B
ELISA
96 Tests
Table of contents:
1. Overview
2. Hematopoiesis products
3. Technical Performances
4. Package Inserts
Cytokines CE- Part5- Hematopoiesis-Differentiation
June 2008
1/5
1. Overview
Hematopoiesis is the process by which all the different cell lineages that form the blood and
immune system are generated from a common pluripotent stem cell.
During the life of an individual, two separate hematopoietic systems exist, both arising
during embryonic development but only one persisting in the adult.
2. Hematopoiesis/Differentiation products - Clinical background
1. IL-5 (Interleukine-5) ELISA KIT
Human IL-5 has been described as T-cell replacing factor and as B-cell growth factor II based on its induction of
proliferation and Ig secretion by activated B cells. Several other activities have furthermore been attributed to
this cytokine, including induction of growth and differentiation of eosinophils from bone marrow stem cells ,
induction of mIL-2R expression on activated B cells and enhancements of IgA secretion by LPS-stimulated Bcells . IL-5 has been shown to be produced by the TH2 subset of human TH clones . The spectrum of biological
activities of IL-5, on B cells as well as other cell types suggests that IL-5 plays an important functional role in
the activities of TH2 cells. IL-5 is a heavily glycosylated glycoprotein with a native m.w. of 45.000 to 60.000, with
multiple subunits of between m.w. 24.000 and 28.000 under reducing conditions.
2. IL-13 (Interleukine-13)ELISA KIT
Introduction
Interleukin-13 (IL-13) was first described as a protein product, designated P600, encoded by an RNA produced
by activated mouse Th2 cells . More recently, the cDNA cloning of the human homologue of P600, human IL13, has been reported . Human IL-13 is a nonglycosylated protein of 132 amino acids with a molecular weight
of 12000Da. The IL-13 gene is located on chromosome 5q23-31, in the same region as the genes encoding IL-3,
IL-4, IL-5, and GM-CSF [9]. It is produced by activated CD4 + and CD8+ T cells, but the expression seems to be
more abundant in CD4+ T cells [5]. Although it is a Th2 cytokine in the mouse, it appears to be produced by
Th0, Th1, and Th2-like human T cell clones.
IL-13 is a pleiotropic cytokine whose spectrum of action encompasses B cells, mononuclear phagocytes, and
large granular lymphocytes . IL-13 induces CD23 expression on B cells, promotes B cell proliferation in
combination with anti-Ig or CD40 antibodies, and stimulates secretion IgE, and IgG4 [2,5,8]. IL-13 has also been
shown to prolong survival of human monocytes and increases surface expression of MHC class II, CD23, and
members of the integrin superfamily, like CD11b, CD11c, CD18, CD29 and CD49e . IL-13 inhibits the
production of a series of cytokines like IL-1, IL-6, TNF- , and IL-8 by activated human monocytes . IL-13
induces IFN- production by NK cells.
Clinical applications
- The capacity of IL-13 to induce IgE synthesis indicates that IL-13 may play an important regulatory role in
IgE-mediated atopic diseases. The measurement of IL-13 in body fluids may thus provide further information
about the pathophysiology of atopic diseases.
Furthermore, IL-13 inhibits HIV-1 replication in primary culture-derived macrophages and represents a
candidate cytokine for the suppression of HIV infection within monocytes and macrophages in vivo.
Cytokines CE- Part5- Hematopoiesis-Differentiation
June 2008
2/5
3. TGF-1 (Transforming Growth Factor-beta 1)ELISA KIT
Introduction
Transforming growth factor- (TGF-) belongs to a family of dimeric 25 kDa polypeptides that are ubiquitously
distributed in tissues and synthesized by many different cells . Three isoforms of transforming Growth Factor-
(TGF-beta1, beta-2 and beta-3) exist in mammals. They play critical roles in growth regulation and
development. Each isoform is encoded by a unique gene on different chromosomes. All three of these growth
factors are secreted by most cell types, generally in a latent form, requiring activation before they can exert
biological activity. The TGF-betas possess three major activities: they inhibit proliferation of most cells, but can
stimulate the growth of some mesechymal cells; they exert immunosuppressive effects and they enhance the
formation of extracellular matrix. Two types of membrane receptors possessing kinase activity are involved in
signal transduction. The TGF-betas are involved in wound repair processes and in starting inflammatory
reaction and then in the resolution through chemotactic attraction of inflammatory cells and fibroblast.
TGF-1 is the first recognized transforming growth factor, its subunits of each 12.5 kDa are bound via
disulphide bridges. TGF-1 is inhibitive to T- and B cell proliferation as well as to maturation and activation of
macrophages. It furthermore inhibits activity of natural killer cells and lymphokine activated killer cells and
blocks production of cytokines.
Measurement of TGF-1 in blood has been advocated for diagnosis of various diseases. TGF-1 has been
shown to be an organizer of responses to neurodegeneration .
Clinical applications
In this context, it turned out to be interesting in monitoring
Alzheimer’s disease , Down’s syndrome, AIDS and
Parkinson’s disease. Serum and cerebrospinal fluid levels of
Multiple Sclerosis patients were shown to be of great value
to monitor remission and acute phases . TGF-1 is thought
to play an important role in bone metabolism, it is
considered a putative regulator of osteoclastic-osteoblastic
interaction, and thus it can be regarded as a marker for
osteoporosis . TGF-1 is involved in the pathogenesis of
glomerular diseases such as diabetic nephropathy and
glomerulosclerosis. TGF-1 has been described to be
functionally connected to major immune system
abnormalities as in autoimmunity (SLE). Serum levels have
been shown to correlate with disease activity in
autoimmune hepatitis Elevated serum levels of TGF-1 are determined in chronic fatigue syndrome patients
and in Guillain-Baire syndrome patients . An inverse correlation with disease activity was described for TGF1 levels in Kawasaki disease and patients with IgA deficiency.
TGF-1 has been confirmed to promote fibrotic processes, thus it is implicated in the myelofibrosis with
myeloid metaplasia. Increased serum levels of TGF-1 in patients affected by thrombotic thromocytopenic
purpura implicate its function on bone marrow haematopoiesis . Determination of circulating TGF-1 turned
out to reflect the various stages in solid tumors as has been shown for cervical cancer , elevations were
furthermore found in prostate cancer , bladder cancer , and liver cancer.
Decreased levels of TGF-1 in the serum of sepsis and acute stroke patients may reflect the changing
immunological-inflammatory status of these patients. Decreased TGF-1 serum levels were described for
patients with acute Plasmodium falciparum malaria .
Cytokines CE- Part5- Hematopoiesis-Differentiation
June 2008
3/5
3. IL-5/ IL-13/ TGF-1-
Technical performances
IL-13 ELISA
IL-5 ELISA
Cat #
Label Format
KAPMS120
Cat #
Biotin-SAV -conjugate
KAPMS113
Label Format
Biotin-SAV conjugate
Standard Format
Concentrated (to be diluted)
Standard Format
Concentrated (to be diluted)
Standard Range
500 - 7.8 pg/ml
Standard Range
100 - 1.6 pg/ml
Sample Size
50 µl
Sample Size
50 µl
Sample Type
Serum, Plasma
Sample Type
Serum, Plasma
Controls Included
no
Controls Included
no
Incubation
190 min with shaking
Sensitivity
1.45 pg/ml
Intra Assay
6.6%
Sensitivity
0.73 pg/ml
Inter Assay
6.8%
Intra Assay
6.0%
Inter Assay
4.6%
Calibration
NIBSC 94/622
135 min with shaking at 100
Incubation
rpm
TGF-beta1 ELISA
Label Format
Standard Format
Standard Range
Sample Size
KAPMS105
HRP-conjugate
Concentrated (to be
diluted)
30 - 0.47 ng/ml
20 µl
Serum, Plasma (need to
Sample Type
be pretreated for 60
min.)
Controls
Incubation Time
Sensitivity
no
1,5
ABSORPTION 450 nm
Cat. Nr.
1
0,5
255 min w ith shaking
23.8 pg/ml
Intra-assay CV
6.7%
Inter-assay CV
8.5%
0
0
5
10
15
20
25
TGF-beta1 CONCENTRATION [ng/ml]
Cytokines CE- Part5- Hematopoiesis-Differentiation
June 2008
4/5
30
Cardiov
ascular
& Salt
Balance
4. Package inserts
The package inserts will be available on BioSource website.
For more information on those products, please visit our website:
www.biosource-diagnostics.com
Cytokines CE- Part5- Hematopoiesis-Differentiation
June 2008
5/5